Frontiers in Antibiotics

Aims & Scope

Frontiers in Antibiotics publishes articles across the spectrum of antibiotic research that explore solutions to antibiotic resistance, development, and delivery to improve the health of the global population.

Led by Field Chief Editor Prof Stephen H.

Gillespie (University of St Andrews, UK), Frontiers in Antibiotics serves as a transparent, reliable platform for scientific exchange across the breadth of the field to address the evolving challenges of antibiotic development and resistance.

Antibiotic resistance is rising globally and the therapeutic pipeline is not keeping up.

Humanity urgently needs to understand the problem and identify solutions.

Genomic tools, the application of big data to the epidemiology of resistance, rapid resistance detection techniques, methods to understand pharmacokinetics and innovative genomic approaches to antibiotic synthesis are transforming the discipline.

Areas of interest include, but are not limited to: • all aspects of antibiotic resistance • antibiotic development and characterization • antibiotics in clinical settings • pharmacology and pharmacokinetics.

Frontiers in Antibiotics explicitly encourages the submission of study protocols.

The editors also encourage contributions and active involvement from early career researchers in all stages of the review and editorial processes.

The journal actively promotes the development and thoughtful application of modern research methods and encourages responsible, reproducible reporting of scientific results.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine and Pharmacology, Toxicology and Pharmaceutics, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 1,950.00 CHF. Learn more.

Explore journals without APCs for alternative publishing options.